aibioLipocine raises its at-the-market program to $50,000,000
Tickers LPCN
Lipocine Inc. filed a prospectus supplement on February 26, 2026 under its sales agreement with A.G.P./Alliance Global Partners. It had sold $10,615,576 of stock under the earlier registration.
Key facts
- Company
- Lipocine Inc. (NASDAQ: LPCN)
- News type
- Financings
- Primary source
- Lipocine Inc. 424B5 (2026-02-26)
Lipocine Inc. (Nasdaq: LPCN) filed a prospectus supplement on February 26, 2026 that increases the amount of common stock it may sell under its sales agreement with A.G.P./Alliance Global Partners. The agreement is dated April 26, 2024. The new total is up to an aggregate of $50,000,000, including shares already sold.
Under the earlier prospectus, Lipocine had registered up to an aggregate of $10,616,169 of common stock. The company said that from April 26, 2024 through the date of the new supplement, it sold 1,603,431 shares for an aggregate purchase price of $10,615,576. From the date of the supplement, the amount that remains available is $39,384,424.
An at-the-market program like this lets a company sell shares gradually through an agent at prevailing market prices. A.G.P. is the sales agent.
Lipocine later disclosed the supplement in a Form 8-K dated March 4, 2026. The shares are offered under a registration statement on Form S-3.